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Neuropaattinen kipu eli hermovauriokipu on seurausta somatosensorisen järjestelmän 
sairaudesta tai vauriosta, kuten kirurgisesta hermovauriosta. Rintasyöpä-leikkauksen 
jälkeinen pitkittynyt leikkausalueen kipu on arviolta 14-31% tapauksista hermovaurio-
kipua. Hermovauriokivun diagnostiikka perustuu samanaikaisten kivun ja tunto-
muutosten osoittamiseen vaurioituneen tuntohermon suhteen neuroanatomisesti 
mielekkäällä alueella. Kliiniset oirekyselyt, kuten Douleur Neuropathique 4 (DN4), 
pyrkivät tunnistamaan hermovauriokivun keskeiset piirteet ja ohjaamaan alkuvaiheen 
diagnostiikkaa. DN4 oirekysely muodostuu haastatteluosasta (engl. DN4 interview 
part, DN4i) sekä tutkimusosasta, jossa huomioidaan lääkärin vastaanotolla mahdol-
lisesti havaitut ihon tuntomuutokset kivun alueella. Yksinään DN4i haastatteluosaa on 
käytetty väestötasoisissa hermovauriokivun seulontatutkimuk-sissa. 
 
Tässä tutkimuksessa verrattiin DN4 oirekyselyn haastatteluosan (DN4i) sekä koko 
kyselyn kykyä erottaa mahdollinen ja varma hermovauriokipu toisistaan. Lisäksi 
tutkittiin muiden tekijöiden mahdollista vaikutusta DN4i haastatteluosan tulkintaan. 
Laajan neurologisen tuntostatustutkimuksen perusteella 163 potilasta luokiteltiin 
mahdollisen (n=27) ja varman (n=136) hermovauriokivun ryhmiin. Potilaat olivat 
rintasyövän vuoksi hoidettuja naisia, joilla oli kirurgin vahvistama hermovaurio (N. 
intercostobrachialis). DN4 kysely täytettiin osana neurologista tuntostatustutkimusta. 
Kyselyn diagnostista osuvuutta tarkasteltiin herkkyys- ja tarkkuuslaskelmin, posi-
tiivisen ja negatiivisen ennustearvon sekä ROC-analyysin avulla suhteessa DN4i ja 
DN4 kliinisiin raja-arvoihin. Muiden tekijöiden vaikutusta DN4i:n tulkintaan tutkittiin 
logistisella regressiolla. 
 
DN4 oirekysely ja sen haastatteluosa (DN4i) osoittautuivat tilastollisesti kykeneviksi 
erottamaan mahdollisen ja varman hermovauriokivun toisistaan. Koko kysely 
osoittautui odotetusti pelkkää DN4i haastatteluosaa herkemmäksi (79.4% vs. 66.2%) 
ja tarkemmaksi (92.6% vs. 77.8%). Hermovauriokivun voimakkuus ei vaikuttanut 
oirekyselyn osioiden diagnostiseen osuvuuteen. Demografiset tekijät, erityisesti 
potilaan ikä, saattavat vaikuttaa DN4i haastatteluosan tulkintaan. Tulos puoltaa DN4 
oirekyselyn käytettävyyttä leikkauksen jälkeisen hermovauriokivun selvittelyssä sekä 
DN4i:n hyödyntämistä hermovauriokivun seulonnassa rintasyövän vuoksi leikatuilla 
potilailla.  
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Backgroung: Douleur Neuropathique 4 (DN4) is a screening questionnaire to help 
identify neuropathic pain (NP) in clinical practice and research. We tested the 
accuracy of the DN4 questionnaire in stratifying possible NP (pNP) and definite NP 
(dNP) in patients operated for breast cancer. 
 
Methods: We studied 163 patients from a longitudinal cohort of breast cancer 
operated patients 4-9 years after surgery. pNP or dNP were classified according to 
the NP grading system. Surgeon-verified intercostobrachial nerve resection was used 
as a confirmatory test for dNP. A receiver-operating characteristic (ROC) curve 
analysis was performed and the area under the curve (AUC) was calculated to test 
the diagnostic accuracy (sensitivity, specificity, positive and negative predictive 
values) of the DN4. Additionally, we studied clinical factors that associated with a 
positive screening outcome in the interview part of the DN4 (DN4i).  
 
Results: DN4i and DN4 showed significant accuracy in stratifying patients with pNP 
or dNP with cut-off scores 3 and 4 resulting to sensitivity of 66.2% and 79.4% and 
specificity of 77.8% and 92.6%, respectively. pNP and dNP patients showed 
differences in sensory descriptors of pain according to DN4i items. Screening 
positive on DN4i associated with dNP and younger age. 
 
Conclusions: Full DN4 could stratify pNP and dNP patients in a chronic postsurgical 
NP patient group operated for breast cancer. Additionally, DN4i showed significant 
accuracy in stratifying pNP and dNP, but an examination is necessary to obtain 
proper accuracy. Demographic factors may have an impact on the screening 
outcome of DN4i.  
 
 









The clinical diagnosis of neuropathic pain (NP) is based on a lesion or disease of the 
somatosensory nervous system with pain and sensory abnormality in the 
neuroanatomically relevant area (Jensen et al., 2011). According to the revised NP 
diagnostic criteria (Finnerup et al., 2016), a surgeon-defined nerve lesion can be 
used to confirm definite NP (dNP).  
 
In cases with surgeon-defined nerve resection, pain without sensory abnormalities on 
a neuroanatomically plausible area is regarded as possible NP (pNP) (Finnerup et 
al., 2016) and with sensory abnormalities, as definitely neuropathic (dNP).  
 
Various screening tools have been developed to identify the main symptoms of NP 
and to help identify NP components (Attal et al., 2018; Bouhassira et al., 2008). NP is 
a common complication after breast cancer surgery and frequently associated with 
intercostobrachial nerve (ICBN) resection (Pereira et al., 2017; Mustonen et al., 
2019). Screening tools may help identify postsurgical NP especially in conditions 
where postsurgical nerve lesion is difficult to identify (Attal et al., 2018). Additionally, 
screening tools for NP may provide information of the pathophysiological 
mechanisms associating with specific NP conditions and sensory phenotypes (Baron 
et al., 2012). 
 
The Douleur Neuropathique 4 (DN4) is a screening questionnaire developed to 
assess both sensory descriptors and signs that relate to NP bedside sensory 
examination (Bouhassira et al., 2005). DN4 has been widely used in various NP 
states with different etiologies (Bouhassira et al., 2005; Mathieson et al., 2015; 
VanDenKerkhof et al., 2018; Attal et al., 2018).  
 
The last three questions in DN4 relate to the bedside sensory examination. These 
have been suggested to be performed as the first step screening examinations for 
NP in routine clinical practice to evaluate the need for further confirmatory diagnostic 
tests or neurological examination (Attal et al., 2018). In the interview part of the DN4 
(DN4i), NP- related sensory descriptors may have relevance in general epidemiology 




Previously, a positive correlation between DN4 and probable NP has been shown 
with surgical nerve lesions, such as in post-thoracotomy pain (Guastella et al., 2011), 
pain after lymph node excision (Høimyr et al., 2011), and pain after breast tumor 
resection (Abdallah et al., 2015). However, it is not known whether DN4 is sensitive 
to stratify pNP and dNP. To address this question, we studied DN4 and DN4i in 
parallel in patients with pNP and dNP from a cohort of patients previously operated 
for breast cancer with a surgeon-defined resection of the ICBN (Mustonen et al., 
2019). Additionally, as sensitivity of the questionnaire may be influenced by clinical 
and demographic characteristics (VanDenKerkhof et al., 2018), we studied factors 






Patients and neuropathic pain assessment 
 
The patients of the present study were recruited from an earlier longitudinal study 
cohort of 1000 women treated for breast cancer (Kaunisto et al., 2013). 251 patients 
with surgeon-verified total or partial ICBN resection were recruited for the current 
cohort. Patient recruitment has previously been described in more detail elsewhere 
(Mustonen et al., 2019). All patients underwent either breast conserving surgery 
(BCS) or mastectomy in combination with either sentinel lymph node biopsy (SLNB) 
or axillary lymph node dissection (ALND). We have previously assessed factors that 
related to persistent postsurgical NP 4 to 9 years after surgery in patients with ICBN 
lesion (Mustonen et al., 2019). There, we examined the patients at a research visit 
and used the NP grading system (Finnerup et al., 2016) to identify pNP and dNP. 
The study was conducted at the Pain Clinic of the Helsinki University Hospital, 
Helsinki, Finland during 2014-2016. The study protocol was approved by the Ethics 
Committee of the Helsinki and Uusimaa Hospital District. All patients gave an 
informed written consent. 
 
We used the revised stepwise NP grading system for patient classification (Finnerup 
et al., 2016, Mustonen et al., 2019). The steps include the following: A) pain in the 
neuroanatomically plausible area with relevant pain history, B) pain associated with 
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at least one sensory abnormality in clinical examination, and C) surgeon-verified 
nerve lesion. After breast cancer surgery, the neuroanatomically plausible area 
includes the breast and the ICBN innervation area (axilla, upper side of chest, lateral 
breast and medial upper arm) (Andersen et al., 2014). pNP patients had pain in the 
neuroanatomically plausible area, but without signs of sensory abnormalities (only 
step A fulfilled). dNP patients had pain with sensory abnormalities within the 
innervation area of the resected ICBN (steps A, B and C fulfilled) (Fig. 1).  
 
All patients in this cohort had a surgeon-verified ICBN resection and this served as a 
confirmatory test (step C) to reach the diagnostic level of dNP. The patients with pain 
and sensory changes only outside the ICBN innervation area (e.g. in medial breast) 
were excluded. In addition, patients without pain (no self-reported or evoked pain) 
and patients with ongoing cancer treatments were excluded from the analyses.  
 
A neurologist (HH) examined the clinical sensory status as follows: static mechanical 
allodynia (compression by finger), light touch (cotton tuft), dynamic touch (painter’s 
brush), pinprick (wooden cocktail stick), cold and warm sensation (metal roller). The 
metal roller was dipped into ice cold water bucket (cold water with ice cubes in it) 
before applying sensory examination for cold. Respectively, the metal roller was 
dipped into hot water before applying sensory examination for warm sensation. Hot 
water was in an electric water boiler and the water had been boiled just before 
dipping the metal roller there. No specific temperature measurement was performed. 
The examiner tested the roller’s temperature to her own skin before testing the 
patient to ensure tolerability of the testing temperature. The sensory examination 
needed for DN4 was included in the clinical sensory status. DN4i was performed by 
reading the questions to the patient out loud.  
 
The examiner was blinded to the ICBN status (no lesion, partial, total, or not 
visualized ICBN lesion in surgeon report) and after all patients had been examined, 
the code was opened for NP classification and the ones with ICBN lesion and pain 
accordingly were chosen for the present study. For illustration, we used patient pain 
drawings and body maps for sensory examination performance. We combined these 
data with the ICBN status and could classify patients according to NP grading system 
(Mustonen et al., 2019). 
6 
 
Douleur Neuropathique 4 (DN4) 
 
The DN4 questionnaire was administered at the research visit by a single researcher 
(HH) to assess neuropathic components of pain (Bouhassira et al., 2005). The DN4 
consists of ten items with a dichotomous yes-no scale. The first part of the 
questionnaire (items 1 to 7, i.e. interview part, DN4i) consists of seven self-report 
items about pain descriptors: ‘Does the pain have one or more of the following 
characteristics? – 1) burning, 2) painful cold, 3) electric shocks’ and ‘Is the pain 
associated with one or more of the following symptoms in the same area? – 4) 
tingling, 5) pins and needles, 6) numbness, 7) itching’. The second part of the 
questionnaire (items 8 to 10, i.e. examination part) consist of three items relating to 
sensory examination: ‘Is the pain located in an area where the physical examination 
may reveal one or more of the following characteristics? – 8) hypoesthesia to touch, 
9) hypoesthesia to pinprick’ and 10) ‘In the painful area, can the pain be caused by 
brushing?’. Thus, the scores range from 0-7 and 0-10 for DN4i and DN4, 
respectively.  
 
We considered scores ≥ 3 for DN4i and ≥ 4 for DN4 as cut-offs for suggestive NP, i.e. 
a positive screening outcome (Bouhassira et al., 2005). At the research visit, the 
interview part (DN4i) was fulfilled and the examining neurologist completed the three-
item clinical part of the DN4. From here on we use the abbreviation DN4i for the DN4 
interview part and DN4 for the full DN4. 
 
 
Demographics, questionnaires and pain assessment 
 
Demographics were collected at the research visit by multiple questionnaires. We 
used the following variables for psychological factors: Hospital Anxiety and 
Depression Scale (HADS) for assessing anxiety and depressive symptoms (Bjelland 
et al., 2002) and Pain Catastrophizing Scale (PCS) for assessing pain associated 
catastrophic thinking (Sullivan et al., 1995).  
 
For pain intensity, we used the worst pain during past week in the operated area 
measured on a Numerical Rating Scale (NRS from 0 to 10, 0 indicating no pain and 
10 the worst imaginable pain intensity) of the Brief Pain Inventory (BPI) (Cleeland et 
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al., 1994). At clinical examination, possible evoked pain was rated by NRS from 0 to 
10, respectively. Patients reported worst other pains (apart from those in the 
operated area) with BPI during past week (NRS 0-10). We considered NRS ≥ 4/10 as 
moderate to severe pain.  
 
Statistical analysis  
 
We used Student’s t-tests, Mann-Whitney U-tests and χ2-tests for continuous 
normally and non-normally distributed variables and categorical variables, 
respectively. Spearman’s rho (rS) was used for correlation of continuous predictor 
variables. Cronbach’s alpha was used for assessing internal consistency of the 
questionnaires. Logistic regression analysis was performed to explore factors, which 
may associate with positive screening in DN4i (sum score ≥ 3). Predictors for logistic 
regression were selected based on correlations with sum scores of DN4i. We used 
backward stepwise method to control for multicollinearity of anxiety (HADS-A) and 
depression (HADS-D). For the same reason, as pain variables in the operated area 
showed strong correlation, only intensity of worst pain in the operated area was 
entered to the final model. Calibration of the logistic model was tested with Hosmer-
Lemeshow test (p>0.05 was preferred).  
 
For analyzing stratifying accuracy of the DN4 questionnaire, we calculated sensitivity, 
specificity, and positive and negative predictive values with 95% confidence intervals. 
We used sum score of 3 and 4 as a cut-off values for NP in DN4i and DN4, 
respectively (Bouhassira et al., 2005). However, Youden index was also used to 
confirm the optimal cut-off values in our data. As the original version of DN4 has 
been validated in patients with at least moderate worst pain intensity, we additionally 
run the analyses separately for patients reporting at least moderate worst pain 
(NRS≥4/10) in the operated area. A receiver-operating characteristic (ROC) curve 
analysis was performed and the area under the curve (AUC) was calculated. P-
values under 0.05 were considered statistically significant. We used SPSS 22.0 









Patients and demographics 
 
The patient flow in the present study is illustrated in Fig. 1. Altogether, 27 pNP and 
136 dNP patients were included in the analyses. Demographics and clinical features 
of the patients are presented in Table 1. dNP patients were significantly younger 
than pNP patients (p=0.007). Moderate to severe evoked pain in the postsurgical or 
nearby area was the most common pain type for both pNP and dNP. Patients with 
dNP reported more often pain elsewhere in the body (NRS≥4) (p=0.044) and had 
received chemotherapy more often than patients with pNP (p=0.039). In both groups, 
the use of NP medications was scarce. Patients did not use analgetics regularly and 
did not use strong opioids.  
 
In clinical sensory examination of the painful postsurgical or nearby area, dNP 
patients presented commonly with hypoesthesia for cold and warm, in 134 patients 
(98.5%) and 132 (97.1%), respectively. Additionally, for cold and warm, they 
presented with hyperesthesia 12 (8.8%) and 11 (8.1%), dysesthesia 15 (11%) and 2 
(1.5%), and allodynia 3 (2.2%) and 0 patients (0%), respectively.  
 
Sensory descriptors of the DN4i and DN4 
 
In Fig. 2, we present the sensory descriptors of DN4i and clinical sensory findings in 
the full form of DN4. Of the sensory descriptors, dNP patients reported more often 
numbness (p<0.001), pins and needles (p<0.001), tingling (p=0.020), and electric 
shocks (p=0.032) compared with pNP patients. We found no differences between 
pNP and dNP on itching, painful cold, nor on burning.  
 
Of the clinical sensory findings in full DN4, 11 dNP patients (8.1%) did not show 
those in full DN4, but other sensory abnormalities. Most of the dNP patients (72.8%, 
99/136) showed abnormalities in two DN4 sensory findings, whereas 16.2% (22/136) 
showed abnormalities in one item, and 2.9% (4/136) in all three items. The most 
common clinical sensory finding was hypoesthesia to touch (84.6%, 115/136), 
following hypoesthesia to pinprick in 75.5% (103/136), and painful brushing in 10.3% 
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(14/136). Patients with pNP did not present any clinical sensory findings in the 
plausible painful area (Fig. 2).  
 
Screening outcome of the DN4i 
 
The sum score of DN4i showed significant negative correlation with age (p<0.001), 
but positive correlation with other variables: intensity of self-reported and evoked pain 
(p<0.05), intensity of worst pain in the operated area (p<0.05), intensity of other 
chronic pains (p<0.001), anxiety (p<0.05), depression symptoms (p<0.001), and pain 
catastrophizing (p<0.01) (Table 2). Intercorrelations between age, psychological, and 
pain variables are presented in the Table S1.  
 
In logistic regression analysis, age showed significant association over all other 
correlating variables (adjusted OR 0.88, 95% CI: 0.83-0.94), p<0.001) with a positive 
DN4i screening (i.e. sum score ≥3) when the dNP was controlled (Table S2).  
 
Stratifying accuracy of the DN4i and DN4 
 
DN4i presented 66.2% sensitivity and 77.8% specificity (Table 3). Of the patients, 
68.1% (111/163) were correctly identified (highest Youden index value of 0.44,Table 
S3). The DN4i sum score presented ≥3 in 96/163 patients (58.9%). pNP and dNP 
was significantly stratified by DN4i (AUC=0.762, 95% CI: 0.661-0.863, p<0.001) (Fig. 
3). 
 
Full DN4 presented 79.4% sensitivity and 92.6% specificity (Table 3). Of the patients, 
81.6% (133/163) were correctly identified (highest Youden index value of 0.72, Table 
S3). The DN4 sum score presented ≥4 in 110/163 patients (67.5%). Two patients 
with pNP screened a sum score ≥4 on DN4. pNP and dNP were significantly stratified 
by DN4 (AUC=0.865, 95% CI: 0.768-0.962, p<0.001) (Fig. 3).  
 
We analyzed separately the DN4i and DN4 sensitivity and specificity for the patients 
with moderate to severe worst pain intensity (NRS≥ 4, n=113) in the postsurgical or 
nearby area. Here, the sensitivity of DN4i was 67.7% and specificity 76.5% whereas 
the sensitivity of DN4 was 79.2% and specificity 94.1% (Table 3). Of the patients, 
69.0% (78/113) and 81.4% (92/113) were correctly identified, respectively. pNP and 
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dNP were significantly stratified by both DN4i (AUC=0.770, 95% CI: 0.646-0.894, 
p<0.001) and DN4 (AUC=0.881, 95% CI: 0.768-0.969, p<0.001). 
 
 
DISCUSSION AND CONCLUSIONS 
 
DN4 showed significant accuracy in stratifying pNP and dNP after surgical peripheral 
nerve lesion in breast cancer operated patients. DN4i showed significant accuracy as 
well, but clinical sensory examination is needed for proper NP diagnostics. Sensory 
descriptors of pain in the DN4i items differed between pNP and dNP patients. dNP 
patients reported more often numbness, pins and needles, tingling, and electric 
shocks compared with pNP. Positive screening in DN4i showed significant correlation 
between clinical and psychological variables and associated with dNP and younger 
age. 
 
It is challenging to verify dNP in postsurgical patients (Abdallah et al., 2015; 
Guastella et al., 2011; Høimyr et al., 2011). NP questionnaires are needed to help 
stratify NP patients. To the best of our knowledge, this is the first study to show that 
with DN4 one may stratify chronic postsurgical NP patients to pNP and dNP groups 
and that DN4i shows significant accuracy as well. However, only clinical sensory 
examination provides proper diagnostic accuracy for NP. 
 
DN4 was designed as a screening tool for NP, something to be used first line by non-
specialists (Bouhassira et al., 2005). In previous studies, DN4i and DN4 have been 
sensitive and specific enough to help in NP diagnostics (Bouhassira et al., 2005; 
Hamdan et al., 2014; Chatila et al., 2017; Timmerman et al., 2017). In our cohort, we 
found that DN4i may be useful as a first step screening of NP in patients with surgical 
nerve resection.  
 
Sensitivity and specificity are key elements in evaluating DN4 validity in stratifying 
pNP and dNP. A previous study used DN4 to screen postsurgical NP in breast 
cancer treated patients. They reported DN4 sensitivity and specificity to be 90% and 
60%, respectively (Abdallah et al., 2015). In line with these, our results of full DN4 
sensitivity and specificity were 79.4% and 92.6%, respectively. Previously, DN4 has 
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correlated to pain severity (Perez et al., 2007). Thus, we analysed sensitivity and 
specificity in patients with pain intensity ≥ 4 on a numerical rating scale (NRS). Now, 
DN4 sensitivity and specificity were 79.2% and 94.1%, respectively. These results 
encourage using DN4 in clinical practice to screen and even stratify pNP and dNP. 
 
Previously, NP has been screened by DN4i in chronic pain patients, including breast 
cancer treated patients (Timmerman et al., 2017). The authors reported DN4i 
sensitivity and specificity of 70% and 67%, respectively. In line with these, sensitivity 
and specificity for DN4i in our cohort was 67.7% and 76.5%, respectively. DN4i may 
be a feasible tool in screening NP in large cohorts (Bouhassira et al., 2005).  
 
It is important to report positive and negative predictive values of a studied 
questionnaire. In a previous study of screening NP in chronic pain patients, DN4 
showed positive and negative predictive values of 92% and 46%, respectively 
(Timmerman et al., 2017). In line with these, our data for DN4i and full DN4 showed 
positive predictive values of 93.8% and 98.2% and negative predictive values of 
31.3% and 47.2%, respectively. These results implicate that if DN4 provides a 
negative result, it might be false negative, i.e. the patient may anyhow have NP. This 
is especially important to consider if DN4 is used in clinical practice.  
 
Patients with NP may have other sensory abnormalities and pain features than what 
are studied by DN4. In our cohort, 8.1% of dNP patients had additional other sensory 
abnormality (such as hyperesthesia and/or changes in thermal sensation) that are 
not included in the DN4. This is important to consider especially in cases of negative 
screening.  
 
Sensory loss to both mechanical and thermal stimuli is common in patients with 
chronic postsurgical pain after breast cancer surgery (Andersen et al., 2017; 
Mustonen et al., 2019), but also hypersensitivity has been reported (Gottrup et al., 
2000; Vilholm et al., 2009). Tingling and numbness, but also other DN4 pain 
characteristics, were common reports in a previous study on chronic pain patients 
including also breast cancer operated women. In the clinical examination, 
hypoesthesia to touch was the most prevalent (Timmerman et al., 2017). In our DN4 
data, patients with dNP reported and presented most typically hypoesthesia to touch 
and pinprick. These findings are in line with other reports of sensory abnormalities 
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after peripheral nerve lesion (Gottrup et al., 2000; Vilholm et al., 2009; Abdallah et 
al., 2015; Andersen et al., 2017; VanDenKerkhof et al., 2018). 
 
dNP and pNP patients did not differ in terms of burning pain and itching. Itching 
involves complex mechanisms both at the peripheral and spinal level, which may be 
influenced by the existing neuropathy (Steinhoff et al., 2019). In a large population 
survey, itching was associated with chronic pain (Dalgard et al., 2007). We are not 
aware of any studies on the role of itch in chronic post-surgical pain. Our results are 
in line with a previous study on DN4 in chronic pain patients where itching did not 
associate with NP component (Timmerman et al., 2017).   
 
In a study of diabetic patients, burning pain was associated with epidermal nerve 
regeneration (Galosi et al., 2018). Our results with relatively infrequent reports on 
burning pain may indicate that other mechanisms are more prevalent in the 
pathophysiology of post-surgical NP after breast cancer treatments.  
 
Previously, psychological variables, such as catastrophizing and mood, have shown 
to have an impact on the screening outcome of the full DN4 questionnaire 
(VanDenKerkhof et al., 2018). Emotional functions and psychological distress, have a 
well-known impact on the severity of NP and may increase disability (Jensen et al., 
2007; Bostic et al., 2017; Mustonen et al., 2019). In our cohort, sum scores of DN4i 
correlated significantly with age, pain variables, and psychological variables. 
However, only dNP and younger age associated with positive screening in DN4i. 
 
Most of our patients presented evoked pain with little or no self-reported pain. 
Evoked pain does not necessarily correspond to clinically meaningful pain but may 
cause the patient to adapt to certain everyday-life habits to prevent pain. Recently, 
evoked pain has more systemically been acknowledged and can be classified as NP 
even in the absence of self-reported pain (Arning and Baron, 2011; Themistocleous 
et al., 2016; Mustonen et al., 2019). 
 
The pathophysiological mechanisms of pain in pNP, where no sensory abnormality 
presents, remain diverse. Pain may be related to breast cancer or its treatments such 
as nerve injury, axon degeneration, infection, hormonal therapy, chemotherapy, or 
radiotherapy. Later, peripheral and central sensitization takes place with changes in 
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neuroplasticity in the periphery, dorsal horn, and central nervous system (von Hehn 
et al., 2012).  
 
Previously, painful hypoesthesia has been shown to associate with loss of small and 
large fiber function (Baron et al., 2017). For NP after a surgical peripheral nerve 
lesion, there most probably is one aetiology, followed by other aetiologies to maintain 
the condition. These factors are e.g central sensitization and partial nociceptive 
deafferentation (Baumgärtner et al., 2002). Also, smaller peripheral nerve lesions 
may take place in surgery and add to NP aetiology. For breast cancer surgery, not 
only ICBN resection, but smaller nerve resections may contribute to NP.  
 
An important issue is how to improve the usage of patient-reported information. DN4i 
may help identify e.g. painful hypoesthesia after surgical nerve lesion and lead to 
better NP diagnostics and treatment. 
 
A strength of the study is a fairly large cohort of chronic postsurgical pain patients 
with surgeon defined ICBN resection. Patients were carefully diagnosed according to 
the NP grading system and could be clinically stratified to pNP and dNP groups. This 
enabled us to test the sensitivity and specificity of DN4 in this cohort.  
 
There are several limitations in this study. The current patient cohort consists of 
patients treated for breast cancer and therefore the generalizability of the findings is 
limited. dNP patients had had chemotherapy more often compared with pNP 
patients. The impact of this remains unclear, because chemotherapy did not show 
significant difference between painful NP and painless ICBN lesion patients in a 
previous study of which the present one is a sub cohort of (Mustonen et al., 2019). 
 
Thermal examination in the present study did not include exact temperature 
measurement, which is a limitation regarding the information of thermal sensitivity. 
However, the thermal testing procedure was similar for all patients. 
 
The negative predictive value of full DN4 of 47% is a limitation. Scoring negative in 




False negative and positive cases pose an important clinical problem. However, 
sensitivity and specificity were good enough to use DN4 as a screening instrument. 
Patients with a negative (false or true) score, however, should be studied further with 
sensory examination.  
 
The aetiology of NP may vary. There might be other reasons for chronic pain than 
chronic postsurgical NP, e.g. myofascial, inflammatory, or central sensitization. 
These reasons cannot be distinguished from dNP by the DN4. 
 
Pain medications may impact the results in DN4i and DN4. However, in our cohort, 
the patients used NP medications scarcely. Thus, bias due to NP medication is not 
very likely. 
 
We performed a logistic regression analysis to study clinical factors that associate 
with a positive screening outcome in DN4i. Subgroup analyses of these factors would 
have been a better approach. However, our sample size was too small for this, but 
large enough to show the association in logistic regression analysis, where age 
showed significant association over all other correlating variables.  
 
This study shows that DN4 and possibly DN4i may help stratify dNP and pNP 
patients after peripheral nerve lesion (ICBN). A wider use of DN4 in the clinic might 
help the first-line physician to consider NP and try NP medication or to refer the 
patient to a pain specialist. The sensory descriptors of DN4i were distinct in dNP and 
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Figure 3. The Receiver operating characteristic (ROC) curves for interview part 
(items 1 to 7, dashed line) and for the total version (items 1 to 10, solid line) of DN4 

















Table 1.  
 
Patient demographics and clinical features. 
 





Patients, n 27 136   
Age, years, mean (SD) 64.9 (6.9) 60.4 (8.0)   0.007a 
Time from index surgery, months, mean (SD) 75.4 (13.1) 77.7 (13.4)   0.418a 
BMI, kg/m2, mean (SD) 27.6 (4.1) 26.3 (3.9)   0.114a 
        
Self-reported painc NRS ≥ 4 in the surgical 
area, number (%) 
5 (18.5) 30 (22.1)   0.497b 
Evoked paind NRS ≥ 4 in the surgical area, 
number (%) 
14 (56.0) 86 (64.7)   0.410b 
Self-reportedc or evoked paind NRS ≥ 4 in the 
surgical area, number (%) 
17 (63.0) 96 (70.6)   0.433b 
Pain elsewhere in the bodye NRS ≥ 4, number 
(%) 
6 (23.1) 53 (44.5)   0.044b 
Current use of TCA, gabapentinoids, or SNRI, 
number (%) 
2 (7.4) 7 (5.1)   0.639b 
Current use of NSAID, acetaminophen, or mild 
opioid, number (%) 
3 (11.1) 26 (19.1)   0.320b 
        
Breast surgery type, number (%)       
  BCS 18 (66.7) 66 (48.5)   0.085b 
  Mastectomy 9 (33.3) 70 (51.5) 
Axillary surgery type, number (%)       
  SLNB  4 (14.8) 11 (8.1)   0.269b 
  ALND 23 (85.2) 125 (91.9) 
Handling of ICBN, number (%)       
  Partially resected 22 (81.5) 88 (64.7)   0.089b 
  Totally resected 5 (18.5) 48 (35.3) 
Chemotherapy, number (%) 20 (74.1) 121 (89.0)   0.039b 
Radiotherapy, number (%) 22 (81.5) 104 (76.5)   0.570b 
Endocrine therapy, number (%) 22 (81.5) 117 (86.0)   0.542b 
    
 
P-values < 0.05 are shown in bold. aStudent’s t-test. bχ2-test. cAssessed as the worst pain 
intensity during past week reported in Brief Pain Inventory (BPI). dEvoked pain was assessed 
at clinical sensory examination; intensity rating is missing from three definite NP patients and 
two possible NP patients. eAnswers missing from 17 definite NP patients and from one 
possible NP patient. Abbreviations: ALND, axillary lymph node dissection; BCS, breast 
conserving surgery; BMI, body mass index; ICBN, intercostobrachial nerve; NP, neuropathic 
pain; NSAID, non-steroidal anti-inflammatory drugs; SD, standard deviation; SLNB, sentinel 






Table 2.  
DN4i sum score correlations with demographics. 
 






Age (years) -0.322 <0.001 
Intensity of self-reported pain (NRS) 0.185 0.018 
Intensity of evoked pain (NRS) 0.168 0.034 
Intensity of worst pain at the operated area (NRS) 0.179 0.022 
Intensity of other chronic pain (NRS) 0.261 0.002 
Anxiety (HADS-A) 0.179 0.023 
Depression (HADS-D) 0.245 0.002 
Pain catastrophizing (PCS) 0.213 0.009 
 
Abbreviations: DN4i, interview version of DN4 (items 1 to 7); NRS, Numerical Rating 
Scale; HADS-A, Hospital Anxiety and Depression Scale - Anxiety; HADS-D, Hospital 
Anxiety and Depression Scale - Depression; PCS, Pain Catastrophizing Scale. Numbers of 
missing values were: intensity of evoked pain, n=4; intensity of other chronic pain, n=19; 
anxiety (HADS-A) and depression (HADS-D) score, n=2; and pain catastrophizing, n=18. 




















Table 3.  
Sensitivity, specificity, positive and negative predictive values, and the 95% confidence intervals for the interview part (items 1 to 7) and 







(%) (95% CI) 
Specificity 
(%) (95% CI) 
Positive predictive value 
(PPV) (%) (95% CI) 
Negative predictive value 
(NPV) (%) (95% CI) 
All patients (n=163) Interview part (DN4i, items 1 to 7) 3 66.2 (58-74) 77.8 (57-90) 93.8 (86-97) 31.3 (21-44) 
Full version (DN4, items 1 to 10) 4 79.4 (71-86) 92.6 (74-99) 98.2 (93-99) 47.2 (33-61) 
Patients with 
NRS≥4/10 (n=113) 
Interview part (DN4i, items 1 to 7) 3 67.7 (57-77) 76.5 (50-92) 94.2 (85-98) 29.5 (17-45) 
Full version (DN4, items 1 to 10) 4 79.2 (69-87) 94.1 (69-99) 98.7 (92-99) 44.4 (28-62) 
 
Diagnostic values are shown separately for all patients (n=163) and for those patients who reported moderate to severe worst pain (NRS≥4/10) in the 















Table S1.  
Intercorrelations between age, psychological, and pain variables.  
 
 1. 2. 3. 4. 5. 6. 7. Cronbach’s 
alpha 
1. Age (years)         
2. Intensity of clinical pain (NRS) 0.014        
3. Intensity of evoked pain (NRS) 0.103 0.021       
4. Intensity of worst pain at the operated area (NRS) 0.076 0.288c 0.878c      
5. Intensity of other chronic pain (NRS) -0.053 0.421c 0.129 0.260c     
6. Anxiety (HADS-A) -0.021 0.244c 0.107 0.163a 0.317c   0.82 
7. Depression (HADS-D) -0.018 0.226b 0.188a 0.255c 0.309c 0.665c  0.88 
8. Pain catastrophizing (PCS) 0.073 0.375c 0.109 0.208b 0.448c 0.416c 0.418c 0.93 
 
Abbreviations: NRS, Numerical Rating Scale; HADS-A, Hospital Anxiety and Depression Scale – Anxiety; HADS-D, Hospital Anxiety and Depression 
Scale – Depression; PCS, Pain Catastrophizing Scale. Numbers of missing values were: intensity of evoked pain, n=4; intensity of other chronic pain, 
n=19; anxiety (HADS-A) and depression (HADS-D) score, n=2; and pain catastrophizing, n=18. Missing data have not been imputed. 
 
For two-tailed significance: a p<0.05, b p<0.01, and c p<0.001. Statistical method Spearman’s rho. Cronbach’s alpha coefficients are presented for 










Table S2.  
Positive screening in DN4i associates with younger age and definite NP in logistic regression analysis.  
 
  Binary logistic regression 
  DN4i sum score ≥ 3 
   
B 
 
OR (95% CI) 
 
p 
Unadjusted model    
 Definite NP (yes) 1.99 7.37 (2.56-21.20) <0.001 
     
Adjusted model    
 Definite NP (yes) 1.84 6.28 (1.90-20.75) 0.003 
 Age (years) -0.13 0.88 (0.83-0.94) <0.001 
 Intensity of worst pain at the operated area (NRS) 0.17 1.19 (0.99-1.43) 0.069 
 Intensity of other chronic pain (NRS) 0.08 1.04 (0.90-1.20) 0.386 
 Anxiety 0.07 0.93 (0.76-1.14) 0.500 
 Depression  0.15 1.16 (0.97-1.40) 0.113 
 Pain catastrophizing 0.06 1.06 (0.99-1.12) 0.079 
 
Abbreviations: DN4i, interview part of DN4 (items 1 to 7); NP, Neuropathic Pain; NRS, Numerical Rating Scale; B, 
unstandardized regression weight; OR, odds ratio; CI, confidence interval.  
 
Hosmer and Lemeshow test for the full (adjusted) model of DN4i had p=0.508. Nagelkerke R square was 0.162 and 
0.383 for the unadjusted and adjusted models for DN4i, respectively. Numbers of missing values were: intensity of 
evoked pain, n=4; pain intensity of other chronic pain, n=19; anxiety (HADS-A) and depression (HADS-D) score, n=2; and 






Table S3.  
Sensitivity, specificity, and Youden Index, corresponding to the sum scores of the 
DN4 questionnaire. 
 
 Douleur Neuropathique 4 (DN4) 
 
 Interview part  
(items 1 to 7) 
 Full version  
(items 1 to 10) 
Sum  
score 
Sensitivity Specificity Youden  
Index 
 Sensitivity Specificity Youden  
Index 
1 94.1 25.9 0.20  97.8 22.2 0.20 
2 83.1 51.9 0.35  95.6 44.4 0.40 
3 66.2 77.8 0.44  90.0 74.1 0.64 
4 44.1 92.6 0.37  79.4 92.6 0.72 
5 21.3 92.6 0.14  60.3 92.6 0.53 
6 5.9 96.3 0.02  36.8 92.6 0.29 
7 0 96.3 0  19.1 92.6 0.12 
8     7.4 92.6 0 
9     0 96.3 0 
10     0 96.3 0 
 
 
 
 
 
 
 
 
